Interactions of hormone replacement therapy, body weight, and bilateral oophorectomy in breast cancer risk

Clinical Cancer Research

Volumn 20, Issue 5, 2014, Pages 1169-1178

  Cui, Yong ^a   Deming Halverson, Sandra L ^a   Beeghly Fadiel, Alicia ^a   Lipworth, Loren ^a   Shrubsole, Martha J ^a   Fair, Alecia M ^a   Shu, Xiao Ou ^a   Zheng, Wei ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; BREAST CANCER; CANCER CLASSIFICATION; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; OVARIECTOMY; POPULATION BASED CASE CONTROL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; BODY MASS INDEX; BODY WEIGHT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; OVARIECTOMY; POSTMENOPAUSE; PUBLIC HEALTH SURVEILLANCE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGISTRIES; RISK; TENNESSEE;

EID: 84895803038     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2094     Document Type: Article

References (48)

1. Narod SA. Hormone replacement therapy and the risk of breast cancer. Nat Rev Clin Oncol 2011;8:669-76.
2. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
3. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic reviewof the literature. Cancer Epidemiol Biomarkers Prev 2004;13:1558-68.
4. Huang Z, Willett WC, Colditz GA, Hunter DJ, Manson JE, Rosner B, et al. Waist circumference, waist: hip ratio, and risk of breast cancer in the Nurses' Health Study. Am J Epidemiol 1999;150:1316-24.
5. van den Brandt PA, Spiegelman D, Yaun SS, Adami HO, Beeson L, FolsomAR, etal.Pooledanalysisofprospectivecohortstudiesonheight, weight, and breast cancer risk. Am J Epidemiol 2000;152:514-27.
6. Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L, et al. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control 2002;13:741-51.
7. Lahmann PH, Hoffmann K, Allen N, van Gils CH, Khaw KT, Tehard B, et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2004;111:762-71.
8. Reeves GK, Beral V, Green J, Gathani T, Bull DMillion Women Study Collaborators. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 2006;7:910-18.
9. Howell A, Chapman M, Harvie M. Energy restriction for breast cancer prevention. Recent Results Cancer Res 2009;181:97-111.
10. Suzuki R, Orsini N, Saji S, Key TJ, Wolk A. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status-a meta-analysis. Int J Cancer 2009;124:698-712.
11. Ritte R, Lukanova A, Berrino F, Dossus L, Tjønneland A, Olsen A, et al. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. Breast Cancer Res 2012;14:R76.
12. Lacroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, et al. Health risks and benefits 5 years after stopping randomized treatment with conjugated equine estrogens in postmenopausal women with prior hysterectomy. JAMA 2011;305:1305-14.
13. Chlebowski RT, Anderson GL. Changing concepts: menopausal hormone therapy and breast cancer. J Natl Cancer Inst 2012;104:517-27.
14. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 2009;6: 718-30.
15. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
16. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.
17. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23.
18. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009;7:4-13.
19. Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Stefanick ML, Wactawski-Wende J, et al. Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev 2011;20:454-63.
20. PariseCA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J 2009;15:593-602.
21. Greene WH. Econometric Analysis, 5th ed. Upper Saddle River, NJ: Prentice Hall; 1993. p. 720-3.
22. Biesheuvel CJ, Vergouwe Y, Steyerberg EW, Grobbee DE, Moons KG. Polytomous logistic regression analysis could be applied more often in diagnostic research. J Clin Epidemiol 2008;61:125-34.
23. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA 1999;28:2091-7.
24. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 2004;96:218-28.
25. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003;289:3254-63.
26. Li CI, Malone KE, Daling JR. Interactions between body mass index and hormone therapy and postmenopausal breast cancer risk (United States). Cancer Causes Control 2006;17:695-703.
27. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res 2006;8:R43.
28. Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, Henderson BE. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study. Am J Epidemiol 2009;169:1251-9.
29. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. CollaborativeGroup on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-59.
30. Rosenberg LU, Einarsdóttir K, Friman EI, Wedrén S, Dickman PW, Hall P, et al. Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2006;15: 2482-8.
31. Beral V, Reeves G, Bull D, Green J Million Women Study Collaborators. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 2011;103:296-305.
32. Ursin G, Tseng CC, Paganini-Hill A, Enger S, Wan PC, Formenti S, et al. Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? J Clin Oncol 2002;20:699-706.
33. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocrin Relat Cancer 2005;12:1071-82.
34. Baglietto L, English DR, Hopper JL, MacInnis RJ,Morris HA, Tilley WD, et al. Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition. Breast Cancer Res Treat 2009;115:171-9.
35. Hankinson SE, Colditz GA, Hunter DJ, Manson JE, Willett WC, Stampfer MJ, et al. Reproductive factors and family history of breast cancer in relation to plasma estrogen and prolactin levels in postmenopausal women in the Nurses' Health Study (United States). Cancer Causes Control 1995;6:217-24.
36. Marsdon J. Hormone-replacement therapy and breast cancer. Lancet Oncol 2002;3:303-11.
37. Karim R, Mack WJ, Hodis HN, Roy S, Stanczyk FZ. Influence of age and obesity on serum estradiol, estrone, and sex hormone binding globulin concentrations following oral estrogen administration in postmenopausal women. J Clin Endocrinol Metab 2009;94:4136-43.
38. Looper MH, Howell AH. Central obesity and breast cancer risk: a systematic review. Obesity 2003;4:157-73.
39. Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 2008;100:1361-7.
40. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005;23:7804-10.
41. Lewis-Wambi JS, Jordan VC. Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res 2009; 11:206.
42. Lewis JS,Meeke K, Osipo C, Ross EA, Kidawi N, Li T, et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Int 2005;97: 1746-59.
43. Jordan VC, Ford LG. Paradoxical clinical effects of estrogen on breast cancer risk: a "new" biology of estrogen-induced apoptosis. Cancer Prev Res 2011;4:633-7.
44. Nichols HB, Visvanathan K, Newcomb PA, Hampton JM, Egan KM, Titus-Ernstoff L, et al. Bilateral oophorectomy in relation to risk of postmenopausal breast cancer: confounding by nonmalignant indications for surgery? Am J Epidemiol 2011;173:1111-20.
45. Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl cancer Inst 2005;97:439-48.
46. Liu Y, Diamant AL, Thind A, Maly RC. Validity of self-reports of breast cancer treatment in low-income, medically underserved women with breast cancer. Breast Cancer Res Treat 2010;119:745-51.
47. Schootman M, Jeffe DB, West MM, Aft R. Self-report by elderly breast cancer patients was an acceptable alternative to surveillance, epidemiology, and end results (SEER) abstract data. J Clin Epidemiol 2005;58:1316-9.
48. Phillips KA, Milne RL, Buys S, Friedlander ML, Ward JH, McCredie MR, et al. Agreement between self-reported breast cancer treatment and medical records in a population-based Breast Cancer Family Registry. J Clin Oncol 2005;23:4679-86.